Achaogen, FDA Agree on SPA for Phase III Antibiotic Drug Trial

Achaogen and the FDA have come to an agreement on a Special Protocol Assessment related to a Phase III trial for plazomicin in patients with gram-negative infections that are resistant to multiple antibiotics.
Drug Discovery & Development Magazine